We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of NAC on Sleep Apnea

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00592618
Recruitment Status : Unknown
Verified May 2007 by Assaf-Harofeh Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : January 14, 2008
Last Update Posted : January 14, 2008
Sponsor:
Information provided by:

Study Description
Brief Summary:
Sleep studies in ESRD patients have identified increased prevalence of Sleep Apnea. Based on current knowledge, treatment aimed at reducing oxidative stress might improve Sleep Apnea in HD patients. The aim of our study is to investigate the effect of N-acetylsysteine on Sleep Apnea in HD patients.

Condition or disease Intervention/treatment
ESRD Sleep Apnea Drug: Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks

  Show Detailed Description

Study Design

Study Type : Interventional  (Clinical Trial)
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sleep Apnea
U.S. FDA Resources

Arms and Interventions


Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • The study will include 20 patients with ESRD, treated with chronic hemodialysis in Assaf Harofeh Medical Center and suffering from sleep disturbances, such as frequent arousals, snoring, daytime sleepiness.

Exclusion Criteria:

Patients will be excluded from the study if they are:

  • Recently started treated with chronic dialysis: less than 3 months.
  • Survived recent major illness, requiring hospitalisation in the last 3 months.
  • Patients with acute renal failure
  • Currently treated with antioxidants ( NAC, vitamin E ets.)
  • Current use of sleep pills
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00592618


Contacts
Contact: Leonid S Feldman, MD +972-8-9779383 leonidf@asaf.health.gov.il

Locations
Israel
Nephrology Division, Assaf Harofeh Medical Center Not yet recruiting
Zerifin, Israel, 70300
Contact: Leonid S Feldman    +972-8-9779383    leonidf@asaf.health.gov.il   
Sponsors and Collaborators
Assaf-Harofeh Medical Center
Investigators
Principal Investigator: Leonid S Feldman, MD Assaf Harofeh MC
More Information

ClinicalTrials.gov Identifier: NCT00592618     History of Changes
Other Study ID Numbers: 346147SLEEP
First Posted: January 14, 2008    Key Record Dates
Last Update Posted: January 14, 2008
Last Verified: May 2007

Keywords provided by Assaf-Harofeh Medical Center:
ESRD
Hemodialysis
Sleep Apnea

Additional relevant MeSH terms:
Apnea
Sleep Apnea Syndromes
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases
Acetylcysteine
N-monoacetylcystine
Antiviral Agents
Anti-Infective Agents
Expectorants
Respiratory System Agents
Free Radical Scavengers
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Antidotes